Clinical trials: Cancer of the Esophagus
Esophageal Squamous Cell Carcinoma
Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma
The primary object of this trial is to evaluate the 2-year local control rate adding extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma.
- Trial name
- NCT02384811
- Testing
- radiation
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Esophageal Cancer
Prospective Comparison of Large vs. Small Diameter Esophageal Stents for Palliation of Malignant Dysphagia
Esophageal cancer often causes difficulty swallowing (dysphagia) that can be relieved by placement of a stent (a flexible, expandable tube that props open the blockage caused by the cancer).
- Trial name
- NCT01894763
- Testing
- Self-expandable metal stent
- Where
- Kenya
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Pancreatic Cancer, Gastric Cancer
COVID - 19 and Advanced Gastro-intestinal Cancer Treatment
A multicenter Italian retrospective study on COVID-19 pandemic condition and advanced Gastro - Intestinal Cancer. Are in Italy increased the new diagnosis of GI cancer in advanced stage in the 2020 compared with 2019, as a…
- Conditions
- Pancreatic Cancer, Gastric Cancer, Esophagus Cancer, Colorectal Cancer
- Trial name
- COVID - AGICT (NCT04686747)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- S.M. Misericordia Hospital
Esophagus Cancer, Chemotherapy Effects
Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients
This is a phase III clinical trial to compare the efficacy of docetaxel plus cisplatin versus 5-Fu plus cisplatin in the first line chemotherapy for advanced or metastatic esophageal squamous carcinoma patients.
- Trial name
- NCT03002064
- Testing
- Docetaxel, Fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal cancer is a highly aggressive tumor. Treatment options are various and range from chemotherapy to radiotherapy and several surgical techniques. Nevertheless, the overall survival rates for this disease remain poor.
- Trial name
- NCT01787006
- Testing
- Cetuximab, Cisplatin, 5-FU, Radiotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- University Hospital Schleswig-Holstein
Esophageal Squamous Cell Carcinoma
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 vs placebo as consolidation chemotherapy after radical concurrent chemoradiotherapy for unresectable locally advanced ESCC.
- Trial name
- NCT03817658
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 725 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
The investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlier, including cancers of the oesophagus (food pipe), stomach, pancreas, liver and bowel.
- Conditions
- Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- BRAVE (NCT07714538)
- Where
- 6 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Chest Wall Tumor, Breast Cancer
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Radiation therapy is an essential treatment for tumors in the chest area, including breast, lung, esophageal, mediastinal cancers, and spine metastases.
- Conditions
- Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- NCT07685938
- Testing
- Atorvastatin and Lisinopril
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Cancer, Gastric Cancer
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Purpose: There remains a great need for novel therapeutic agents and treatment strategies for advanced esophagogastric cancer. Preclinical and clinical studies have demonstrated increased EGFR expression in a significant…
- Conditions
- Esophageal Cancer, Gastric Cancer, Neoplasm Metastasis
- Trial name
- NCT00130689
- Testing
- Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Active Surveillance
Statistical Analysis Plan for the SANO-trial: Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Active Surveillance for Oesophageal Cancer
An active surveillance approach is proposed after completion of neoadjuvant chemoradiotherapy (nCRT) for carcinoma of the oesophagus. In this SANO (i.e.
- Conditions
- Esophageal Cancer, Active Surveillance, Neoadjuvant Chemoradiotherapy, Surgical Oncology
- Trial name
- SANO (NCT05953181)
- Testing
- Active surveillance
- Where
- Netherlands
- Volunteers
- 776 people
- Sponsor
- Erasmus Medical Center
Adenocarcinoma
Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI
This trial will be conducted to evaluate the efficacy, safety and tolerability of SUNITINIB as add-on therapy with a widely used second-line palliative FOLFIRI chemotherapy in patients with chemo-refractory advanced or metastatic…
- Trial name
- SUN-CASE (NCT01020630)
- Testing
- Sunitinib
- Where
- 16 sites in Germany
- Volunteers
- 91 people
- Sponsor
- PD Dr Markus Möhler
Head and Neck Squamous Cell Carcinoma, Lung Cancer
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating Durvalumab in conjunction with SBRT or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer
- Trial name
- ABIMMUNE (NCT03212469)
- Testing
- Durvalumab, Tremelimumab, SBRT
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Esophagus Cancer
The Effect of Parenteral Nutrition Supplement on Esophagectomy Patients
Malnutrition is common in esophagus cancer patients, especially after surgery therapy. Whether parenteral supplement with enteral nutrtion is benificial for patients after esophagectomy is controversial, when compared with…
- Trial name
- NCT01669356
- Testing
- Parenteral supplement with enteral nutrition for patients after esophagectomy, Enteral Nutrition alone for patients after esophagectomy
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Cancer, Gastric Cancer
DX-8951f in Treating Patients With Metastatic Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have…
- Trial name
- NCT00017212
- Testing
- exatecan mesylate
- Where
- 6 sites in United States, Canada
- Sponsor
- Daiichi Sankyo
Barrett's Esophagus, CIS
Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus
Patient's with High Grade Dysplasia, Carcinoma in situ or Early Adenocarcinoma in Barrett's Esophagus are injected with HPPH and one day later are endoscopically treated with light from a laser.
- Conditions
- Barrett's Esophagus, CIS, HGD
- Trial name
- NCT01238042
- Testing
- HPPH
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Esophageal Squamous Cell Carcinoma
Changhai Multimodal Esophageal Cancer Cohort
The burden of esophageal squamous cell carcinoma (ESCC) in China is substantial, with 85% of the cancers being in the progressive stage.
- Trial name
- CMECC (NCT06410677)
- Testing
- DNA Sequencing, RNA Sequencing
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wangluowei
Esophageal Cancer
Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer
The primary purpose of this study is to assess the safety and feasibility of giving TNFerade™ with 5-FU, Cisplatin and radiation therapy to patients with locally advanced, esophageal cancer prior to surgical resection.
- Trial name
- NCT00051480
- Testing
- TNFerade
- Where
- 12 sites in United States
- Sponsor
- GenVec
Advanced Esophageal Carcinoma
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer
This study aims to evaluate the efficacy and safety of a combination treatment of chidamide, camrelizumab, and apatinib in patients with advanced esophageal cancer.
- Trial name
- NCT06745193
- Testing
- chidamide+Camrelizumab+Apatinib, Irinotecan or Docetaxel or Paclitaxel
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Peking University
Neurocognitive Impairment, Delirium
Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic
RATIONALE: Gathering information about how often problems with neurocognitive functioning occur in patients with newly diagnosed upper aerodigestive tract cancers may help doctors learn more about the disease.
- Conditions
- Neurocognitive Impairment, Delirium, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00533884
- Testing
- Assessment of therapy complications, Neurocognitive assessment, Quality-of-life assessment
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Vanderbilt University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.